Here is some important information on how to determine which test strategy is right for your organization:
When choosing which test to use, it is important to understand the purpose of the testing (e.g., diagnostic vs. screening), analytic performance of the test within the context of the level of community transmission
, need for rapid results, and other considerations. The COVID-19 Viral Testing Tool
helps healthcare providers and individuals understand their COVID-19 testing options. After test results are in, the tool can help interpret results and guide next steps.
Most antigen tests that have received EUA from FDA
are authorized for testing symptomatic persons within the first 5, 6, 7, 12, or 14 days of symptom onset. Accumulation of data on the performance of antigen tests in different situations has helped guide the use of these tests as screening tests in asymptomatic people to detect or exclude SARS-CoV-2 infection. See FDA’s recommendations
for healthcare providers using SARS-CoV-2 diagnostic tests for screening asymptomatic individuals for COVID-19.
Also see information from the Centers for Medicare & Medicaid Services (CMS) on Updated CLIA SARS-CoV-2 Molecular and Antigen Point of Care Test Enforcement Discretion.